Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Authors: Dolinska, Monika, Cai, Huan, Månsson, Alma, Shen, Jingyi, Xiao, Pingnan, Bouderlique, Thibault, Li, Xidan, Leonard, Elory, Chang, Marcus, Gao, Yuchen, Medina, Juan Pablo, Kondo, Makoto, Sandhow, Lakshmi, Johansson, Anne-Sofie, Deneberg, Stefan, Söderlund, Stina, Jädersten, Martin, Ungerstedt, Johanna, Tobiasson, Magnus, Östman, Arne, Mustjoki, Satu, Stenke, Leif, Le Blanc, Katarina, Hellström-Lindberg, Eva, Lehmann, Sören, Ekblom, Marja, Olsson-Strömberg, Ulla, Sigvardsson, Mikael, Qian, Hong

Source: In Blood 6 July 2023 142(1):73-89

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Authors: Söderlund, Stina ^*, Persson, Inger, Ilander, Mette, Guilhot, Joëlle, Hjorth-Hansen, Henrik, Koskenvesa, Perttu, Richter, Johan, Saussele, Susanne, Mustjoki, Satu, Olsson-Strömberg, Ulla

Source: In Leukemia Research March 2020 90

Profound but Transient Changes in the Inflammatory Milieu of the Blood During Autologous Hematopoietic Stem Cell Transplantation

Authors: Wiberg, Anna, Olsson-Strömberg, Ulla, Herman, Stephanie, Kultima, Kim, Burman, Joachim

Source: In Biology of Blood and Marrow Transplantation January 2020 26(1):50-57

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Authors: Ossenkoppele, Gert, Pagoni, Maria N., Söderlund, Stina, Escoffre-Barbe, Martine, Etienne, Gabriel, Dengler, Jolanta, Huguet, Francoise, von Bubnoff, Nikolas, Klamova, Hana, Faber, Edgar, Guilhot, Francois, Lotfi, Kourosh, Rea, Delphine, Brümmendorf, Tim H., de Greef, Gorgine E., Stenke, Leif, Nicolini, Franck E., Legros, Laurence, Burchert, Andreas, Voglova, Jaroslava, Charbonnier, Aude, Gyan, Emmanuel, Kunzmann, Volker, Westerweel, Peter E., Saussele, Susanne, Richter, Johan, Guilhot, Joelle, Gruber, Franz X, Hjorth-Hansen, Henrik, Almeida, Antonio, Janssen, Jeroen J W M, Mayer, Jiri, Koskenvesa, Perttu, Panayiotidis, Panayiotis, Olsson-Strömberg, Ulla, Martinez-Lopez, Joaquin, Rousselot, Philippe, Vestergaard, Hanne, Ehrencrona, Hans, Kairisto, Veli, Machová Poláková, Katerina, Müller, Martin C, Mustjoki, Satu, Berger, Marc G, Fabarius, Alice, Hofmann, Wolf-Karsten, Hochhaus, Andreas, Pfirrmann, Markus, Mahon, Francois-Xavier

Source: In The Lancet Oncology June 2018 19(6):747-757

KIT signaling is dispensable for human mast cell progenitor development

Authors: Dahlin, Joakim S., Ekoff, Maria, Grootens, Jennine, Löf, Liza, Amini, Rose-Marie, Hagberg, Hans, Ungerstedt, Johanna S., Olsson-Strömberg, Ulla, Nilsson, Gunnar

Source: In Blood 19 October 2017 130(16):1785-1794

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.

Authors: Mahon, Francois-Xavier¹ (AUTHOR) francois-xavier.mahon@u-bordeaux.fr, Pfirrmann, Markus² (AUTHOR), Dulucq, Stéphanie^3,4 (AUTHOR), Hochhaus, Andreas⁵ (AUTHOR), Panayiotidis, Panayiotis⁶ (AUTHOR), Almeida, Antonio⁷ (AUTHOR), Mayer, Jiri⁸ (AUTHOR), Hjorth-Hansen, Henrik⁹ (AUTHOR), Janssen, Jeroen J.W.M.¹⁰ (AUTHOR), Mustjoki, Satu^11,12 (AUTHOR), Martinez-Lopez, Joaquin¹³ (AUTHOR), Vestergaard, Hanne¹⁴ (AUTHOR), Ehrencrona, Hans^15,16 (AUTHOR), Machová Poláková, Katerina¹⁷ (AUTHOR), Olsson-Strömberg, Ulla¹⁸ (AUTHOR), Ossenkoppele, Gert¹⁰ (AUTHOR), Berger, Marc G.¹⁹ (AUTHOR), Etienne, Gabriel^4,20 (AUTHOR), Dengler, Jolanta^21,22 (AUTHOR), Brümmendorf, Tim H.^23,24 (AUTHOR)

Source: Journal of Clinical Oncology. 2024 Supplement 16, Vol. 42, p1875-1880. 11p.

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Authors: Warfvinge, Rebecca ^*, Geironson, Linda ^*, Sommarin, Mikael N.E. ^*, Lang, Stefan, Karlsson, Christine, Roschupkina, Teona, Stenke, Leif, Stentoft, Jesper, Olsson-Strömberg, Ulla, Hjorth-Hansen, Henrik, Mustjoki, Satu, Soneji, Shamit, Richter, Johan, Karlsson, Göran

Source: In Blood 27 April 2017 129(17):2384-2394

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Authors: Söderlund, Stina, Christiansson, Lisa, Persson, Inger, Hjorth-Hansen, Henrik, Richter, Johan, Simonsson, Bengt, Mustjoki, Satu, Olsson-Strömberg, Ulla, Loskog, Angelica

Source: In Leukemia Research November 2016 50:95-103

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Authors: Christiansson, Lisa, Mustjoki, Satu, Simonsson, Bengt, Olsson-Strömberg, Ulla, Loskog, Angelica S.I., Mangsbo, Sara M.

Source: In EuPA Open Proteomics June 2014 3:37-47

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Authors: Höglund, Martin ^*, Sandin, Fredrik, Hellström, Karin, Björeman, Mats, Björkholm, Magnus, Brune, Mats, Dreimane, Arta, Ekblom, Marja, Lehmann, Sören, Ljungman, Per, Malm, Claes, Markevärn, Berit, Myhr-Eriksson, Kristina, Ohm, Lotta, Olsson-Strömberg, Ulla, Själander, Anders, Wadenvik, Hans, Simonsson, Bengt, Stenke, Leif, Richter, Johan

Source: In Blood 15 August 2013 122(7):1284-1292

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Authors: Brioli, Annamaria ^*, Lomaia, Elza ^*, Fabisch, Christian ^*, Sacha, Tomasz ^*, Klamová, Hana ^*, Morozova, Elena ^*, Golos, Aleksandra ^*, Ernst, Philipp ^*, Olsson-Strömberg, Ulla ^*, Mayer, Jiri ^*, Nicolini, Franck E., Bao, Han ^*, Castagnetti, Fausto, Patkowska, Elzbieta ^*, Hirschbühl, Klaus ^*, Paczkowska, Edyta ^*, Parry, Anne ^*, Voskanyan, Astghik ^*, Saussele, Susanne, Franke, Georg-Nikolaus ^*, Kiani, Alexander ^*, Faber, Edgar ^*, Lewandowski, Krzysztof ^*, Krause, Stefan W. ^*, Dammann, Elke ^*, Anhut, Peter ^*, Gil, Justyna ^*, Südhoff, Thomas ^*, Heibl, Sonja ^*, Pfirrmann, Markus ^*, Hochhaus, Andreas, Lauseker, Michael ^*

Source: In Blood 15 November 2022 140 Supplement 1:818-820

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Authors: Simonsson, Bengt, Gedde-Dahl, Tobias, Markevärn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Björeman, Mats, Flogegård, Max, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Ohm, Lotta, Räsänen, Anu, Sinisalo, Marjatta, Själander, Anders, Strömberg, Ulla, Bjerrum, Ole Weiss, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin, Sandin, Fredrik, Nagler, Arnon, Nielsen, Johan Lanng, Hjorth-Hansen, Henrik, Porkka, Kimmo

Source: In Blood 22 September 2011 118(12):3228-3235

Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.

Authors: Vaivade, Aina, Wiberg, Anna, Khoonsari, Payam Emami, Carlsson, Henrik, Herman, Stephanie, Al-Grety, Asma, Freyhult, Eva, Olsson-Strömberg, Ulla, Burman, Joachim, Kultima, Kim

Source: Lipids in Health & Disease; 7/7/2023, Vol. 22 Issue 1, p1-15, 15p

Subject Terms: NATALIZUMAB, HEMATOPOIETIC stem cell transplantation, METABOLOMICS, CERAMIDES, PLATELET-rich plasma, MULTIPLE sclerosis, HEMATOPOIETIC stem cells, CENTRAL nervous system diseases

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

Authors: Geelen, Inge G.P., Gullaksen, Stein-Erik, Ilander, Mette M., Olssen-Strömberg, Ulla, Mustjoki, Satu, Richter, Johan, Blijlevens, Nicole M.A., Smit, Willem M., Gjertsen, Bjorn T., Gedde-Dahl, Tobias, Markevärn, Berit, Koppes, Malika M.A., Westerweel, Peter E., Hjorth-Hansen, Henrik, Janssen, Jeroen J.W.M.

Source: Annals of Hematology; Jun2023, Vol. 102 Issue 6, p1395-1408, 14p

Subject Terms: CHRONIC myeloid leukemia, NILOTINIB, IMATINIB

Gene expression analysis identifies a genetic signature potentially associated with response to α-IFN in chronic phase CML patients

Authors: Hagberg, Anette, Olsson-Strömberg, Ulla, Wickenberg-Bolin, Ulrika, Göransson, Hanna, Isaksson, Anders, Bengtsson, Mats, Höglund, Martin, Simonsson, Bengt, Barbany, Gisela

Source: In Leukemia Research 2007 31(7):931-938

Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation

Authors: Huuhtanen, Jani, Adnan-Awad, Shady, Theodoropoulos, Jason, Forstén, Sofia, Warfvinge, Rebecca, Dufva, Olli, Bouhlal, Jonas, Dhapola, Parashar, Duàn, Hanna, Laajala, Essi, Kasanen, Tiina, Klievink, Jay, Ilander, Mette, Jaatinen, Taina, Olsson-Strömberg, Ulla, Hjorth-Hansen, Henrik, Burchert, Andreas, Karlsson, Göran, Kreutzman, Anna, Lähdesmäki, Harri, Mustjoki, Satu

Source: In Blood 2 November 2023 142 Supplement 1:3146-3146

Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening.

Authors: Schaal, Wesley, Ameur, Adam, Olsson-Strömberg, Ulla, Hermanson, Monica, Cavelier, Lucia, Spjuth, Ola

Source: Cancer Informatics; 7/15/2022, Vol. 21, p1-8, 8p

Subject Terms: CHRONIC myeloid leukemia, SEQUENCE analysis, TECHNOLOGY transfer

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study.

Authors: Dahlén, Torsten, Edgren, Gustaf, Ljungman, Per, Flygt, Hjalmar, Richter, Johan, Olsson‐Strömberg, Ulla, Wadenvik, Hans, Dreimane, Arta, Myhr‐Eriksson, Kristina, Zhao, Jingcheng, Själander, Anders, Höglund, Martin, Stenke, Leif

Source: American Journal of Hematology; Apr2022, Vol. 97 Issue 4, p421-430, 10p

Tusen svenska kvinnoår : svensk kvinnohistoria från vikingatid till nutid
1000 svenska kvinnoår

Authors: Ohlander, Ann-Sofie., Strömberg, Ulla-Britt.

Access URL: http://hdl.handle.net/2027/mdp.39015056306262

Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study.

Authors: Flygt, Hjalmar, Söderlund, Stina, Stentoft, Jesper, Richter, Johan, Koskenvesa, Perttu, Mustjoki, Satu, Majeed, Waleed, Lübking, Anna, Dreimane, Arta, Markevärn, Berit, Stenke, Leif, Myhr Eriksson, Kristina, Gjertsen, Bjørn Tore, Gedde‐Dahl, Tobias, Dimitrijevic, Andreja, Udby, Lene, Olsson‐Strömberg, Ulla, Hjorth‐Hansen, Henrik

Source: European Journal of Haematology; Dec2021, Vol. 107 Issue 6, p617-623, 7p

Subject Terms: PROTEIN-tyrosine kinase inhibitors, DASATINIB, CHRONIC myeloid leukemia, DIAGNOSIS, DISEASE progression